A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of SB 207266 in Patients With Symptomatic Persistent Atrial Fibrillation (AF)

GlaxoSmithKline0 sites520 target enrollmentNovember 2001

ConditionsFibrillation, Atrial

InterventionsSB-207266 Placebo

DrugsSB-207266

Overview

Phase: Phase 2
Intervention: SB-207266
Conditions: Fibrillation, Atrial
Sponsor: GlaxoSmithKline
Enrollment: 520
Primary Endpoint: Time-to-first symptomatic AF (atrial fibrillation)
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).

Registry

clinicaltrials.gov

Start Date

November 2001

End Date

December 2003

Last Updated

11 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

GlaxoSmithKline

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Symptomatic persistent atrial fibrillation requiring DC cardioversion.
•Duration of AF \>48 hrs. \<6 months

Exclusion Criteria

•Concomitant Class I and/or III anti-arrhythmic drugs.
•Amiodarone treatment within 3 months of the study.
•Other inclusion or exclusion criteria to be determined by the physician and study sponsor.